Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 19/20 | 0.74 |
| ▸ | MAOA | P21397 | 2/20 | 0.72 |
| ▸ | MAOB | P27338 | 2/20 | 0.72 |
| ▸ | BCHE | P06276 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319124 | 0.94 | ACHE (0.84) | ACHEMAOAMAOBBCHE | |
| Ethyl Fumarate SCHEMBL3300402 | 0.93 | ACHE (0.66) | ACHEMAOAMAOBBCHE | |
| Fumaric Acid SCHEMBL3294767 | 0.87 | ACHE (0.71) | ACHEMAOAMAOBBCHE | |
| Fumaric Acid SCHEMBL3302279 | 0.87 | ACHE (0.71) | ACHEMAOAMAOBBCHE | |
| SCHEMBL3895981 | 0.87 | ACHE (0.98) | ACHEMAOAMAOBBCHE | |
| SCHEMBL13449663 | 0.87 | ACHE (0.98) | ACHEMAOAMAOBBCHE | |
| SCHEMBL3895985 | 0.87 | ACHE (0.98) | ACHEMAOAMAOBBCHE | |
| Fumaric Acid SCHEMBL5320406 | 0.84 | ACHE (0.73) | ACHEMAOAMAOBBCHE | |
| Fumaric Acid SCHEMBL5320401 | 0.84 | ACHE (0.73) | ACHEMAOAMAOBBCHE | |
| Ladostigil SCHEMBL3301711 | 0.84 | ACHE (1.00) | ACHEMAOAMAOBBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093848-A1 | PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2010-04-15 | — | — | US | disclosed |
| US-7625946-B2 | Propargylated aminoindans, processes for preparation, and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2009-12-01 | — | — | US | disclosed |
| WO-2007100583-A2 | PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-09-07 | — | — | WO | disclosed |
| US-20070203232-A1 | Propargylated aminoindans, processes for preparation, and uses thereof | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203232-A1 | Propargylated aminoindans, processes for preparation, and uses thereof | PRMT3, PRMT1, PNMT | ACHE 76/4885MAOA 511/4885MAOB 510/4885 |
| US-20100093848-A1 | PROPARGYLATED AMINOINDANS, PROCESSES FOR PREPARATION, AND USES THEREOF | DNPEP, PEPD, ACHE | ACHE 3/4885MAOA 482/4885MAOB 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.